 is not covered by this report. Such remuneration is 
resolved annually by the annual general meeting and disclosed in note 9 on pages 42-43 in 
the annual report 2024. 
Key developments during 2024 
The CEO summarizes the company’s overall performance in his statement on page 3 in the 
annual report 2024 and in the directors’ report on pages 21-30. 
The company’s remuneration guidelines: scope, purpose and deviations 
A prerequisite for the successful implementation of the company’s business strategy and 
safeguarding of the company’s long-term interests, including its sustainability, is that the 
company is able to recruit and retain highly competent senior executives. In order to 
achieve this, the company must offer a competitive total remuneration on market terms. 
The company’s remuneration guidelines enable the company to offer executives a 
competitive total remuneration on market terms. Under the remuneration guidelines, 
remuneration to senior executives may consist of the fol w.synactpharma.com/en/governance/general-meetings/ . 
No remuneration has been reclaimed.

Table 1 – Total remuneration of the CEO in 2024 (kSEK)* 
 
 
 
 
 
Name of director 
(position) 1 
Fixed remuneration 2 
Variable remuneration 
3 
4 
5 
6 
 
Base salary1 
Other benefits One-year 
variable Multi-year 
variable Extraordinary 
items2 Pension 
expense Total 
remuneration Proportion of 
fixed and variable 
remuneration 
Jeppe Øvlesen 
Torbjørn Bjerke 
 
 (CEO3) 
1,355 
 
2,600 
 
 
- 
- 
 
- 
- 
 
3,600 
 
281 
 
780 
1,636 
 
6,980 
100/0 
 
100/0 
* The table reports remuneration earned in 2024. Disbursement of any payments may or may not have been made the same year. The remuneration in Table 1 
includes remuneration paid by companies within the SynAct Group. 
1 Base salary includes holiday pay. 
2 Extraordinary items include a severance pay of SEK 3,600 thousand to Torbjørn Bjerke. 
3 Fixed remuneration and pension to CEO includes Jeppe Øvlesen for the period after the AGM 2024 (  to finance and 
development progress. The Board has evaluated the performance related to the 
performance criteria objectives and has resolved that the CEO will receive kSEK 482 as 
variable remuneration related to performance 2024. 
Comparative information on the change of remuneration and company performance 
Table 2 – Change of remuneration and company performance over the last five reported 
financial years (RFY) (kSEK)* 
 
RFY 2024 RFY 2023 RFY 2022 RFY 2021 
CEO remuneration 8,616 8,941 3,655 1,942 
Group operating profit -89,980 -224,496 -105,705 -76,699 
Average remuneration on a 
full-time equivalent basis of 
employees1 of the SynAct 
Group 1,065 798 801 1,328 
* From and including the financial year 2021, which is the first financial year for this type of remuneration report. SynAct has not previously compiled data 
from previous financial years in this respect; such data will be reported in the future remuneration reports for the respective financial years for comparison. 